Difference between revisions of "Regimen classes"
Jump to navigation
Jump to search
m (→Named classes) |
m |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
=Generic classes= | =Generic classes= | ||
==Allogeneic HSCT== | ==Allogeneic HSCT== | ||
| − | ==Chemoradiotherapy | + | ==Chemoradiotherapy-based regimen== |
| − | |||
| − | |||
| − | ==Chemotherapy== | + | ==Chemotherapy-based regimen== |
===Biochemotherapy=== | ===Biochemotherapy=== | ||
===High-dose chemotherapy with auto HSCT=== | ===High-dose chemotherapy with auto HSCT=== | ||
===Intensive chemotherapy=== | ===Intensive chemotherapy=== | ||
| − | ==Endocrine therapy== | + | ==Endocrine therapy-based regimen== |
| − | ==Radiotherapy== | + | ==Radiotherapy-based regimen== |
==Single-agent regimen== | ==Single-agent regimen== | ||
===Single-agent cytotoxic chemotherapy=== | ===Single-agent cytotoxic chemotherapy=== | ||
| − | ===Single-agent | + | ===Single-agent endocrine therapy=== |
===Single-agent immunotherapy=== | ===Single-agent immunotherapy=== | ||
===Single-agent targeted therapy=== | ===Single-agent targeted therapy=== | ||
==Multi-agent regimen== | ==Multi-agent regimen== | ||
| + | ===Multi-agent cytotoxic chemotherapy=== | ||
=Named classes= | =Named classes= | ||
| Line 25: | Line 24: | ||
==Alkylator-based regimen== | ==Alkylator-based regimen== | ||
==Anthracycline-based regimen== | ==Anthracycline-based regimen== | ||
| + | ===Doxorubicin-based regimen=== | ||
==Anti-CD20-based regimen== | ==Anti-CD20-based regimen== | ||
| Line 43: | Line 43: | ||
==Fluoropyrimidine-based regimen== | ==Fluoropyrimidine-based regimen== | ||
| + | ===Fluoropyrimidine-based chemoradiotherapy=== | ||
| + | ====5-FU-based chemoradiotherapy==== | ||
===5-FU-based regimen=== | ===5-FU-based regimen=== | ||
| + | ==Fluoropyrimidine- and platinum-based regimen== | ||
==Irinotecan-based regimen== | ==Irinotecan-based regimen== | ||
| Line 51: | Line 54: | ||
===Oxaliplatin-based regimen=== | ===Oxaliplatin-based regimen=== | ||
===Platinum-based chemoradiation=== | ===Platinum-based chemoradiation=== | ||
| + | ===Platinum-taxane-based regimen=== | ||
===Platinum doublet=== | ===Platinum doublet=== | ||
==Taxane-based regimen== | ==Taxane-based regimen== | ||
===Docetaxel-containing regimen=== | ===Docetaxel-containing regimen=== | ||
| + | ===Paclitaxel-containing regimen=== | ||
| + | |||
==Temozolomide-based regimen== | ==Temozolomide-based regimen== | ||
Latest revision as of 13:51, 21 October 2023
The purpose of this page is to define regimen classes that will be used in the HemOnc ontology; it is not for other purposes at this time.
Generic classes
Allogeneic HSCT
Chemoradiotherapy-based regimen
Chemotherapy-based regimen
Biochemotherapy
High-dose chemotherapy with auto HSCT
Intensive chemotherapy
Endocrine therapy-based regimen
Radiotherapy-based regimen
Single-agent regimen
Single-agent cytotoxic chemotherapy
Single-agent endocrine therapy
Single-agent immunotherapy
Single-agent targeted therapy
Multi-agent regimen
Multi-agent cytotoxic chemotherapy
Named classes
All classes in this category have at least one named agent or class of agents other than the most generic classes of chemotherapy, immunotherapy, etc.
Alkylator-based regimen
Anthracycline-based regimen
Doxorubicin-based regimen
Anti-CD20-based regimen
Rituximab-containing regimen
Anti-HER2-based regimen
Trastuzumab-based regimen
Anti-VEGF biologic therapy
Bevacizumab-containing regimen
Dacarbazine-based regimen
Endocrine-based regimen
Androgen receptor-directed therapy
Antiestrogen therapy
Fludarabine-based regimen
Fluoropyrimidine-based regimen
Fluoropyrimidine-based chemoradiotherapy
5-FU-based chemoradiotherapy
5-FU-based regimen
Fluoropyrimidine- and platinum-based regimen
Irinotecan-based regimen
Pemetrexed-containing regimen
Platinum-based regimen
Cisplatin-based regimen
Oxaliplatin-based regimen
Platinum-based chemoradiation
Platinum-taxane-based regimen
Platinum doublet
Taxane-based regimen
Docetaxel-containing regimen
Paclitaxel-containing regimen
Temozolomide-based regimen
Tyrosine kinase inhibitor therapy
BRAF TKI therapy
EGFR TKI therapy
VEGFR inhibitor therapy
Modeled classes
This unusual category includes regimens that are "like" another regimen, without exactly specifying how they are like.